Erratum to: Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome: RITUXIMAB FOR SYMPTOMATIC FATIGUE AND ORAL DRYNESS IN PRIMARY SS (Arthritis & Rheumatology, (2017), 69, 7, (1440-1450), 10.1002/art.40093);Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome

Arthritis and Rheumatology

Volumn 69, Issue 7, 2017, Pages 1440-1450

  Bowman, Simon J ^a   Everett, Colin C ^b   O'Dwyer, John L ^b   Emery, Paul ^c   Pitzalis, Costantino ^d   Ng, Wan Fai ^e   Pease, Colin T ^c   Price, Elizabeth J ^f   Sutcliffe, Nurhan ^g   Gendi, Nagui S T ^h   Hall, Frances C ⁱ   Ruddock, Sharon P ^b   Fernandez, Catherine ^b   Reynolds, Catherine ^b   Hulme, Claire T ^b   Davies, Kevin A ^j   Edwards, Christopher J ^k   Lanyon, Peter C ^l   Moots, Robert J ^m   Roussou, Euthalia ⁿ   Giles, Ian P ^o   Sharples, Linda D ^p   Bombardieri, Michele ^d   more..

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f GREAT WESTERN HOSPITAL   (United Kingdom)

^g ROYAL LONDON HOSPITAL   (United Kingdom)

^h BASILDON HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF SUSSEX   (United Kingdom)

^k UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^l UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^m UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

ⁿ KING GEORGE HOSPITAL   (United Kingdom)

^o UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^p LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROXYCHLOROQUINE; NONSTEROID ANTIINFLAMMATORY AGENT; PILOCARPINE; PLACEBO; RITUXIMAB; RO ANTIBODY; ANTIRHEUMATIC AGENT;

ABDOMINAL PAIN; ADULT; ANAPHYLAXIS; ANKLE EDEMA; ARTICLE; CHEST INFECTION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; DIARRHEA; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECHINOCOCCOSIS; EPIGLOTTITIS; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME PATIENT REPORTED INDEX; FATIGUE; FEMALE; FLOW RATE; FRACTURE; HEART INFARCTION; HUMAN; HYPOTENSION; INFUSION RELATED REACTION; LACRIMAL FLUID; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MIDDLE AGED; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANCREAS TUMOR; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SEPSIS; SJOEGREN SYNDROME; TENSION FREE VAGINAL TAPE; THORAX PAIN; TREATMENT RESPONSE; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; XEROSTOMIA; AGED; CLINICAL TRIAL; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; ODDS RATIO; PATIENT-REPORTED OUTCOME; SJOGREN'S SYNDROME; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RITUXIMAB; SJOGREN'S SYNDROME; TREATMENT OUTCOME; UNITED KINGDOM; VISUAL ANALOG SCALE; XEROSTOMIA;

EID: 85020237160     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.41484     Document Type: Erratum

References (34)

1. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol 2000;12:391–8.
2. Bowman SJ, Booth DA, Platts RG, UK Sjögren's Interest Group. Measurement of fatigue and discomfort in primary Sjögren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004;43:758–64.
3. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. Arch Intern Med 1999;159:174–81.
4. Papas AS, Sherrer YS, Charney M, Golden HE, Medsger TA Jr, Walsh BT, et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren's syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol 2004;10:169–77.
5. Gottenberg JE, Ravaud P, Puéchal X, Le Guern V, Sibilia J, Goeb V, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA 2014;312:249–58.
6. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
7. Devauchelle-Pensec V, Pennec Y, Morvan J, Pers JO, Daridon C, Jousse-Joulin S, et al. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20). Arthritis Care Res (Hoboken) 2007;57:310–7.
8. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740–50.
9. St.Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, et al. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum 2013;65:1097–106.
10. Carubbi F, Cipriani P, Marrelli A, Benedetto P, Ruscitti P, Berardicurti O, et al. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther 2013;15:R172.
11. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541–4.
12. Meijer JM, Meiners PM, Vissink A, Spijkervet FK, Abdulahad W, Kamminga N, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960–8.
13. Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, et al. Treatment of primary Sjögren syndrome with rituximab: a randomized trial. Ann Intern Med 2014;160:233–42.
14. Brown S, Navarro Coy N, Pitzalis C, Emery P, Pavitt S, Gray J, et al. The TRACTISS Protocol: a randomised double blind placebo controlled clinical TRial of Anti-B-Cell Therapy In patients with primary Sjögren's Syndrome. BMC Musculoskelet Disord 2014;15:21.
15. Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A, et al. EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. Ann Rheum Dis 2011;70:968–72.
16. Bowman SJ, Hamburger J, Richards A, Barry RJ, Rauz S. Patient-reported outcomes in primary Sjögren's syndrome: comparison of the long and short versions of the Profile of Fatigue and Discomfort—Sicca Symptoms Inventory. Rheumatology (Oxford) 2009;48:140–3.
17. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 1997;36:551–9.
18. Seror R, Ravaud P, Bowman SJ, Baron G, Tzioufas A, Theander E, et al, on behalf of the EULAR Sjögren's Task Force. EULAR Sjögren's Syndrome Disease Activity Index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103–9.
19. Vitali C, Palombi G, Baldini C, Benucci M, Bombardieri S, Covelli M, et al. Sjögren's Syndrome Disease Damage Index and Disease Activity Index: scoring systems for the assessment of disease damage and disease activity in Sjögren's syndrome, derived from an analysis of a cohort of Italian patients. Arthritis Rheum 2007;56:2223–31.
20. Barry RJ, Sutcliffe N, Isenberg DA, Price E, Goldblatt F, Adler M, et al. The Sjögren's Syndrome Damage Index—a damage index for use in clinical trials and observational studies in primary Sjögren's syndrome. Rheumatology (Oxford) 2008;47:1193–8.
21. Bowman SJ, Sutcliffe N, Isenberg DA, Goldblatt F, Adler M, Price E, et al. Sjögren's Systemic Clinical Activity Index (SCAI)–a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome. Rheumatology (Oxford) 2007;46:1845–51.
22. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–99.
23. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 2008.
24. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. April 4, 2013. URL: https://www.nice.org.uk/process/pmg9/resources/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781.
25. Joint Formulary Committee. British national formulary. 67th ed. London: BMJ Group and Pharmaceutical Press; 2013.
26. Department of Health. National schedule of reference costs. URL: https://www.gov.uk/government/publications/nhs-reference-costs-2013-to-2014.
27. Curtis L. Unit costs of health & social care 2014. Canterbury: Personal Social Services Research Unit; 2014.
28. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095–108.
29. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521–33.
30. Devauchelle-Pensec V, Morvan J, Rat AC, Jousse-Joulin S, Pennec Y, Pers JO, et al. Effects of rituximab therapy on quality of life in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 2010;29:6–12.
31. Moerman RV, Arends S, Meiners PM, Brouwer E, Spijkervet FK, Kroese FG, et al. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. Ann Rheum Dis 2014;73:472–4.
32. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, et al. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. Rheumatology (Oxford) 2015;54:1699–708.
33. Devauchelle-Pensec V, Jousse-Joulin S, Mariette X, Berthelot JM, Perdriger A, Hachulla E, et al. Impact of different end points on the patient cohort size needed to demonstrate the efficacy of a therapeutic intervention in PSS: a post hoc analysis of the TEARS study (Tolerance and Efficacy of Rituximab in Primary Sjögren Syndrome study) [abstract]. Arthritis Rheum 2013;65 Suppl:S1235.
34. Jousse-Joulin S, Devauchelle-Pensec V, Cornec D, Marhadour T, Bressollette L, Gestin S, et al. Ultrasonographic assessment of salivary gland response to rituximab in primary Sjögren's syndrome. Arthritis Rheumatol 2015;67:1623–8.